Center for Regenerative Medicine
and Cell Based Therapies (CRMCBT)
1st Annual Retreat
August 17 – 18, 2012
Mohican State Park Lodge
Speaker Biographies
Eben Alsberg, PhD
Associate Professor, Biomedical Engineering and Orthopaedic Surgery
Case Western Reserve University
National Center for Regenerative Medicine
Eben Alsberg, PhD, received his B.S.E. in Mechanical Engineering and Material Science and Biomedical
Engineering, cum laude, from Duke University in 1994. Eben then went to graduate school at the University of
Michigan in Ann Arbor where he received an M.S.E. in Mechanical Engineering (1998), an M.S.E. in Biomedical
Engineering (1998), and a Ph.D. in Biomedical Engineering (2002) under the guidance of Dr. David J. Mooney. His
graduate training was in design, synthesis, and characterization of biomaterials, bioactive factor delivery, tissue
engineering, and biomechanics and cell mechanobiology obtained through. He began his graduate studies in Dr.
Steve Goldstein’s Orthopaedic Research Laboratory investigating the roles biomaterials and mechanics play in
healing fracture defect and distraction osteogenesis models. He then continued on at Michigan as an NIH-NIDCR
Graduate Fellow engineering biomaterial systems for bioactive delivery and tissue engineering applications. The
work received several honors including the Biovalley Young Investigator Award for best paper presentation at the
4th International Meeting of the Tissue Engineering Society International (2001), 1st Place in the American
Association for Dental Research/Warner-Lambert Hatton Award Competition (2002), 2 nd Place in the International
Association for Dental Research/Warner-Lambert Hatton Award Competition (2002), the International Association
for Dental Research/Lion Dental Research Award in the Periodontal Research Category (2002), and the American
Association for Dental Research William J. Gies Award for the best paper published in the Journal of Dental
Research (2003). Following his graduate studies, he was a Postdoctoral Research Fellow in the Vascular Biology
Program at Harvard Medical School for two years investigating biomaterial and mechanical regulation of lung
development and endothelial cell behavior under the guidance of Dr. Donald E. Ingber. His postdoctoral studies
further complemented his graduate training in cell and tissue mechanics with additional molecular, cell, and vascular
biology experience to support research contributions in the quickly evolving and multidisciplinary field of
regenerative medicine.
Eben took a faculty position in 2005 at Case Western Reserve University, where he is currently an associate
professor of Biomedical Engineering and Orthopaedic Surgery and serves as Director of the Stem Cell and
Engineered Novel Therapeutics Laboratory. His lab focuses on the engineering of new technologies to regenerate
tissues and treat cancer through the development of novel biomaterials and microenvironments. He’s co-authored
over 52 peer reviewed papers, in journals such as the PNAS, Biomaterials, Advanced Functional Materials, JBMR,
1
Nanoletters, and JACS, and 92 abstracts and conference proceedings. His work has been recognized with the 2008
Ellison Medical Foundation New Scholar in Aging Award and the Crain’s Cleveland Business 2009 Forty Under 40
Award. His laboratory focuses on engineering functional biologic replacements to repair damaged or diseased
tissues in the body. They use the complex signals that are implicated in tissue morphogenesis, repair, and
homeostasis as a template for the development of innovative biomaterial systems for tissue regeneration. Through
the precise temporal and spatial presentation of mechanical forces, soluble bioactive factors, and biomaterial
physical and biochemical properties, they aspire to create biomaterials and microenvironments that regulate cell
gene expression and new tissue formation. Some areas of active investigation include understanding the influence
of mechanics on cell behavior and tissue formation, engineering innovative biomaterials and drug delivery vehicles
for functional tissue regeneration and cancer therapy, controlling stem cell fate decision, developing technologies to
control the temporal and spatial presentation of signals to regulate cell behavior, and studying cell-cell interactions.
Shideng Bao, PhD
Stem Cell Biology and Regenerative Medicine
Associate Staff, Cleveland Clinic
National Center for Regenerative Medicine
Associate Staff in the Department of Stem Cell Biology & Regenerative Medicine at Cleveland Clinic Lerner
Research Institute. Before he joined LRI, he was an Associate Professor in Departments of Radiation Oncology and
Neurosurgery at University of Colorado Denver. Dr. Bao completed his PhD thesis research at Dana-Faber Cancer
Institute, and did his postdoctoral trainings at Baylor College of Medicine and Duke University Medical Center. He
became an Assistant Professor in 2005 at Duke Brain Tumor Center where he started his research program on
glioblastoma (GBM) stem cells (GSCs). His lab studies signaling pathways regulating the stem cell properties in
GSCs and neural stem cells (NSCs). His team has identified several critical signaling molecules that control the
tumorigenic potential of GSCs. His recent research works have been published in Cancer Cell (2011), Nature Cell
Biology (2011) and EMBO J (2011). The goal of his research is to develop novel therapeutic approaches to target
cancer stem cells to effectively improve GBM treatment.
Alicia L. Bertone, DVM, PhD, Diplomate ACVS
Equine Orthopedic Surgeon and Trueman Family Endowed Chair and Professor, Veterinary Clinical
Sciences
CRMCBT
The Ohio State University
Dr. Bertone received her Bachelor of Science degree (1977), DVM degree (1982) and internship (1983) from
Cornell University, subsequently completed a combined surgery residency/PhD program (1987) at Colorado State
University and joined the surgery faculty at Louisiana State University that same year. Dr. Bertone became board
certified as a Diplomate in the American College of Veterinary Surgeons in 1988 and joined the surgery faculty at
The Ohio State University late in 1989. Dr. Bertone focused her clinical and research efforts in the field of
orthopedics and became a full professor in 1997. Dr Bertone has served as an equine orthopedic surgeon at The
2
Ohio State University Galbreath Equine Center for over 20 years, managing cases and training veterinary students
and equine surgery residents. Dr.Bertone has mentored many PhD and Masters of Science graduate students, surgery
residents and research fellows and has developed a reputation for a quality and productive research program and a
strong sports medicine and orthopedic elective surgical caseload. Dr. Bertone has consistently been one of the top
extramurally funded researchers in the College of Veterinary Medicine and has greater than 150 peer reviewed
scientific publications. After completing a 1-year sabbatical at the Center for Molecular Orthopedics at Harvard
University (2000), Dr. Bertone was appointed to the Trueman Family Endowed Chair (2001) and established the
Comparative Orthopedic Molecular Medicine Suite and Applied Laboratories. Dr Bertone has retained a clinical
appointment at the Galbreath Equine Center at The Ohio State University where she focuses her clinical efforts on
equine sports medicine and orthopedic surgery. Dr. Bertone is a member of The Dorothy M. Davis Heart and Lung
Research Institute, is an adjunct full professor in the Department of Orthopedics in the College of Medicine, and
serves as the Director of Industry and Basic Research for the Sports, Health and Performance Institute at OSU. Dr
Bertone’s research focus is in the study of comparative orthopedic and sports injuries as well as cell and molecular
therapy for the treatment of cartilage and bone repair. Dr. Bertone has been active in veterinary and human
orthopedic associations and has been regularly invited to participate in national and international scientific meetings
for her expertise in orthopedics and orthopedic research.
Christopher Breuer, MD
Deputy Vice Chair, Research
Director, Tissue Engineering Program
CRMCBT
The Ohio State University
Co-Director, Tissue Engineering Program
Nationwide Children’s Hospital
Christopher Breuer will be joining the faculty at Ohio State in September 2012. He was recruited from Yale
University where he is an Associate Professor of Surgery at the School of Medicine. He is a member of the
Vascular Biology and Therapeutics Program, the Yale Tissue Engineering Initiative, and Director of the Tissue
Engineering Microsurgery Core. His research focuses on the development and translation of tissue engineered
vascular conduits for use in congenital heart surgery. His basic science work investigates the cellular and molecular
mechanisms underlying neovessel formation and the development of tissue engineered vascular graft stenosis. He is
the principal investigator of the first FDA clinical trial evaluating the use of tissue engineered vascular grafts in
children.
Herbert Bresler, PhD
Chief Scientist
Health and Life Sciences Global Business
Battelle
Herbert Bresler, PhD is a Senior Research Leader at Battelle and Chief Scientist for the Health & Life Sciences
Global Business (HLSGB). Herb develops strategic technology focus and implements scientific programs to
advance Battelle’s competitive position in scientific and technical services. He manages the HLSGB Intellectual
3
Property portfolio and Independent Research and Development activities, and coordinates health and life science
research collaborations with outside investigators. Herb has led several interdisciplinary programs, including
advancing Battelle’s integrated capabilities in systems biology and efforts to apply Battelle’s unique combination of
expertise in Biotechnology and Medical Devices to the development of improved manufacturing for Cell Therapy
and Tissue Engineered products. He currently leads Battelle’s initiative in Engineered Drug Delivery, providing a
holistic approach to the design and development of Drug-Device Combination Products.
Prior to joining Battelle, Herb operated the Laboratory of Immunotherapeutics at the James Cancer Hospital at The
Ohio State University where he managed production of autologous cellular therapies for cancer and HIV. He is an
Adjunct member of the Department of Molecular Virology, Immunology and Medical Genetics, and serves on
several committees and advisory boards for OSU. Herb has two Bachelor’s degrees from The University of
Maryland (Biological Science 1978 and Secondary Science Education 1980) and a Ph.D. in Immunology and
Infectious Diseases from The Johns Hopkins University School of Hygiene & Public Health (1989).
Hiranmoy Das, Ph.D.,
Associate Professor, Cardiovascular and Internal Medicine
CRMCBT
The Ohio State University
Hiranmoy Das, PhD, Associate Professor, Department of Internal Medicine, The Wexner Medical Center at the
Ohio State University, received his graduate, masters and PhD degrees from University and Calcutta, India. He had
postdoctoral training in Hyogo Medical Center for Adults, Akashi, Japan and Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA, where he became faculty. His laboratory currently focuses on development
of hematopoitic stem cell therapy for clinical application using human umbilical cord blood to treat degenerative
diseases. His laboratory has developed a nanofiber-based ex-vivo stem cell expansion technology, which not only
provides essential number of functional stem cells also preserves stem cell characteristics. To enhance therapeutic
potential, nanofiber-expanded stem cells could be genetically modified with various factors to test in preclinical
models of hind limb ischemia, myocardial ischemia, stroke-mediated ischemia, osteoporosis, and cutaneous wounds.
Current investigations use immunocompromised murine, rat, and swine models for relevant studies. Molecular
aspects of stem cell functionality are also being investigated in these animal models after cell-based therapy. To test
feasibility and efficacy a small clinical trial with nanofiber-expanded stem cells is underway in critical limb
ischemic patients.
Ali Dhinojwala, PhD,
Department Chair, H. A. Morton Professor of Polymer Science
Akron University
Professor Dhinojwala received his Bachelors of Technology Degree in Chemical Engineering from the Indian
Institute of Technology, India in 1986 and his Ph.D. from Northwestern University in Chemical Engineering in
4
1994. Thereafter, he was a Research Scientist at the Department of Materials Science at the University of Illinois,
Urbana-Champaign, from 1994 to 1996. At GE Plastics, he worked on developing plastics for DVDs from 1996 to
1997. In 1997 he joined The University of Akron in the Department of Polymer Science. Professor Dhinojwala is
currently Chair of the Department of Polymer Science and H. A. Morton Chair Professor of Polymer Science. He
has been a recipient of the NSF-CAREER Award and NSF-Creativity Award from the National Science Foundation.
He is also a recipient of the Young Faculty Award from 3M Corporation.
Professor Dhinojwala’s current research interest is in the area of adhesion and bio-adhesion. His group has
developed light-based techniques to understand the physical properties of molecules at interfaces. Recently, his
interest in bio-adhesion has led them to develop synthetic adhesives inspired by geckos and spiders.
Avner Friedman, PhD
Professor, Mathematical Biosciences Institute
CRMCBT
The Ohio State University
Avner Friedman is a Distinguished University Professor, where he also serves as the Director of the Mathematical
Biosciences Institute (MBI). He received his Ph.D. degree in 1956 from the Hebrew University. He was Professor of
Mathematics at Northwestern University (1962-1985), and a Duncan Distinguished Professor of Mathematics at
Purdue University (1985-1987). From 1987-1997, Dr. Friedman directed the Institute for Mathematics and its
Applications (IMA) at the University of Minnesota, which is devoted to bridging the gap between mathematical
theory and its applications and between academia and industry. From 1994-2001 he was the Director of the
Minnesota Center for Industrial Mathematics and in 1996 he became a Regents Professor at the University of
Minnesota. Dr. Friedman's research interests include partial differential equations, stochastic processes,
mathematical modeling, free boundary problems, and control theory. He published twenty books and over 400
research papers. He serves on numerous editorial boards. He was the Chair of the Board of Mathematical Sciences
(1994-1997) and the President of the Society of Industrial and Applied Mathematics (1993-1994). Dr. Friedman has
been awarded the Sloan Fellowship (1962-1965), the Guggenheim Fellowship (1966-7), the Stampacchia Prize
(1982) and the National Science Foundation Special Creativity Award (1983-85; 1991-93). He is a Fellow of the
National Academy of Arts and Sciences (Since 1987) and a member of the National Academy of Sciences (since
1993). In 2001 Dr. Friedman became the first director of the MBI. His current research includes tumor modeling,
wound healing, and the role of the immune system in various diseases.
Samir Ghadiali, Ph.D., MS
Associate Professor, Biomedical Engineering,
Associate Professor, Pulm, Allergy, Crit Care & Sleep
CRMCBT
The Ohio State University
Dr. Ghadiali is an Associate Professor in the Biomedical Engineering department at The Ohio State University and
is the Director of Graduate Studies in BME at OSU. He holds an adjunct appointment in the Department of Internal
5
Medicine, Division of Pulmonary, Allergy, Critical Care & Sleep Medicine at the Wexner Medical Center and is a
full member of the Davis Heart and Lung Research Institute. He received his B.S. in Chemical Engineering from
Cornell University (1994) and his M.S. (1998) and Ph.D. (2000) in Biomedical Engineering from Tulane University.
Prior to joining OSU in 2008, he was the Frank Hook Assistant Professor of Bioengineering at Lehigh University
and did his post-doctoral work at the University of Pittsburgh. Dr. Ghadiali's laboratory integrates engineering and
molecular biology approaches to address important clinical problems such as Acute Lung Injury, Otitis Media and
Lung Cancer. This combined engineering-biology approach is leading to novel therapies for these respiratory
disorders. Dr. Ghadiali has expertise in cellular engineering, epithelial cell injury, lung inflammation and
mechanobiology. His lab also uses multi-scale, imaged-based computational models to develop novel patientspecific therapies. Dr. Ghadiali is a Parker B. Francis Fellow in Pulmonary Research and has won New Investigator
and CAREER awards from the U.S. National Committee on Biomechanics and the National Science Foundation. He
has published extensively in the biomedical engineering and respiratory physiology fields and his laboratory is
currently funded by the NIH, NSF and Howard Hughes Medical Institute.
Gayle Gordillo, M.D., FACS
Associate Professor of Plastic Surgery
CRMCBT
The Ohio State University
Gayle Gordillo, MD, FACS, is an Associate Professor of Surgery at The Ohio State University. She is a boardcertified plastic surgeon and an oral board examiner for the American Board of Plastic Surgery. She is the
Chairman of the basic science research committee for the American Society of Plastic Surgeons. She is an
accomplished surgeon-scientist with experience as a principal investigator for both sponsored clinical trials, FDA
clinical trials and NIH funded basic and translational research. She currently has R01 funding from NIH to study
mechanisms regulating hemangioma growth. She is co-founder and director of clinical research for the
Comprehensive Wound Center at The Ohio State University Medical Center and she founded and directs the
Hemangioma and Vascular Malformation Clinic at Nationwide Children’s Hospital. These entities serve as both
clinical care and translational research outlets for her surgical specialty interests in wound healing and
hemangiomas. She also serves as a scientific advisor to 2 companies. She is one of 54 women from across the
country selected to participate in the Executive Leadership in Academic Medicine (ELAM) program to gain formal
leadership training as part of the class of 2010-2011.
Denis C. Guttridge, Ph.D.
Associate Professor, Molecular Virology, Immunology & Medical Genetics
CRMCBT
The Ohio State University
Denis C. Guttridge, Ph.D. is the Chair, Graduate Student Studies, Dept. Molecular Virology, Immunology, and
Medical Genetics, Director, Ohio State University – Nationwide Children’s Hospital Research for Muscle Biology,
Associate Professor, Department of Molecular Virology, Immunology and Medical Genetics, involved with the
Program in Human Cancer Genetics at the OSU Comprehensive Cancer Center and Co-Director of the OSU
Comprehensive Cancer Center Pelotonia Training Program. He received his Ph.D. at the University of California,
Irvine and Postdoctoral at University of North Carolina, Chapel Hill. Dr. Guttridge’s laboratory is focused on the
6
NFgnaling pathway and the regulation of cell growth and cellular differentiation. His familiarity with NFextends over 12 years, beginning with postdoctoral training at the University of North Carolina, at Chapel Hill and
continuing on in his own research group at the Ohio State University. The goal of the laboratory is to understand
whether NFthis property of NF- B, the lab utilize skeletal muscle as a model system of differentiation. In vitro and in vivo
genetic approaches have revealed insight on the function of NFunderstanding the contribution of this signaling pathway in several muscle disease conditions such as Duchenne
muscular dystrophy, cachexia, and more recently rhabdomyosarcoma. They are using a combination of mouse
models and pharmacological approaches to ascertain the requirement and underlying mechanisms of NFin Duchenne muscular dystrophy.
Michael Gilkey, MBA, MS
Marketing and Operations Manager
National Center for Regenerative Medicine
Case Western Reserve University
Michael Gilkey is the Marketing and Operations Manager for the National Center for Regenerative Medicine
(NCRM). He is responsible for the development and execution of organizational strategy, planning and execution of
both external and internal marketing efforts, coordination of graduate, undergraduate, and high school education
programs and provides administrative, financial and operational oversight. Michael Gilkey earned two degrees from
Case Western Reserve University. The first was a MS in Biomedical Engineering and the second was a MBA with
concentrations in Bioscience Entrepreneurship and Marketing. He also has a BS in Biological Engineering from
Louisiana State University.
Derek Hansford, Ph.D.
Associate Professor, Biomedical Engineering,
Associate Professor, Materials Science
CRMCBT
The Ohio State University
Derek Hansford, PhD, received his BS in 1994 from Case Western Reserve University and his MS and PhD in 1996
and 1999 from the University of California, Berkeley, all in Materials Science and Engineering. His research as a
student was on silicon MEMS and microdevice fabrication, characterization, and application to biomedical systems.
He joined the OSU Biomedical Engineering faculty in 1999, focusing on development and application of polymer
microfabrication techniques for biomedical applications. He also holds appointments in Materials Science and
Engineering and Biophysics at OSU.
The Hansford lab works on a broad range of research, including the development of polymer microdevices for
manipulation, isolation, and testing of single cells and cell clusters. Specific applications include
micro/nanostructured scaffolds for tissue engineering, cell isolation microwells for high throughput cell biology
research, microelectrodes for individual cell and cortical column monitoring, and micro/nanofluidics for cell and
biomolecular manipulation and measurement.
7
John Harrington, PhD
Executive Vice President and Chief Scientific Officer, Athersys, Inc.
Executive Member, National Center for Regenerative Medicine
Dr. Harrington co-founded Athersys in October 1995 and has served as Athersys' Executive Vice President and
Chief Scientific Officer and as a director since Athersys' founding. Dr. Harrington led the development of the RAGE
technology as well as its application for gene discovery, drug discovery and commercial protein production
applications. He is a listed inventor on 20 issued or pending U.S. patents, has authored 20 scientific publications,
and has received numerous awards for his work, including being named one of the top international young scientists
by MIT Technology Review in 2002. Dr. Harrington has overseen the therapeutic product development programs at
Athersys since their inception, and during his career he has also held positions at Amgen and Scripps Clinic. He
received his Ph.D. in Cancer Biology from Stanford University and his B.A. in Biochemistry and Cell Biology from
the University of California at San Diego.
Xiaoming (Shawn) He, Ph.D.
Associate Professor, Biomedical Engineering
CRMCBT
The Ohio State University
Xiaoming(Shawn) He, Ph.D., received his PhD in Mechanical Engineering from the University of Minnesota, Twin
Cities and did his postdoctoral training in Harvard Medical School and Massachusetts General Hospital. He joined
The Ohio State University as an associate professor of Biomedical Engineering in 2011 after spending four years as
an assistant professor of Mechanical and Biomedical Engineering at the University of South Carolina, Columbia. He
is also an investigator of the Davis Heart and Lung Research Institute and a member of the James Comprehensive
Cancer Center at OSU. Recently, He was named as a research scholar of the American Cancer Society.
He’s research is focused on developing multiscale biomaterials for cell microencapsulation, cell banking, and
drug/gene delivery with two major biomedical applications: Cell-based medicine and cancer therapy. For the former,
He’s lab has been generating biomimetic microtissue using stem cells and developing microvascularized tissue for
both tissue regeneration and cell-based therapy. For the latter, He’s lab is developing novel drug/gene delivery
strategies to improve the safety and efficacy of cancer treatment.
Alex Huang, MD, PhD
Assistant Professor of Pediatrics
8
Pathology & Biomedical Engineering
Director of Pediatric Hematology-Oncology Fellowship Program
Rainbow Babies & Children's Hospital
Case Western Reserve University School of Medicine
National Center for Regenerative Medicine
Dr. Huang received B.S. in Chemistry and M.S. in Biochemistry and Molecular Biology from the University of
Chicago. He then entered MSTP at Johns Hopkins where he studied cross-presentation and identification of tumor
antigens. After pediatric residency at Johns Hopkins Hospital and pediatric hematology/oncology at JHU/NCI, he
became a senior post-doctoral fellow at NIAID where he applied intravital 2-photon microscopy in the study of
immune cell interaction in lymph nodes and the gut. Since 2006 Dr. Huang became an assistant professor of
Pediatric and clinical fellowship director of pediatric heme/onc at Rainbow-UH/CWRU with a secondary
appointment in Pathology and BME, and a membership in the Case Comprehensive Cancer Center. Current funded
projects in Huang’s lab include studying the role of tissue microenvironment in tumor and immune cell recruitment
in the bone marrow, CNS, and peripheral tissues, with funding from NCI, NIAID, the Dana Foundation, Cancer
Research Institute, St. Baldrick’s Foundation, Gabrielle’s Angel Foundation, Hyundai Hope-on-wheel, Alex’s
Lemonade Stand, Steven G. AYA Research Fund, and NCRM / CCCC pilot grants.
Jed Johnson, Ph.D.,
Chief Technology Officer
Nanofiber Solutions
Jed Johnson, PhD, is Chief Technology Officer and co-founder of Nanofiber Solutions. He received his MS in 2008
and PhD in 2010 from The Ohio State University in Materials Science and Engineering with a focus on biomaterials
and electrospinning to create nanofiber scaffolds for life science applications. Dr. Johnson led the team that won the
2009 Deloitte Business Plan Competition through the Fisher College of Business to start Nanofiber Solutions. He
has since served as PI on several NIH and NSF STTR and SBIR grants focused on 3-D cell culture devices for highthroughput drug discovery and stem cell applications. Dr. Johnson designed and produced the first synthetic
nanofiber trachea in the world that was combined with autologous stem cells and successfully implanted into a
patient at the Karolinska Institutet in Sweden in November 2011. Additional tracheal transplant surgeries are
scheduled for Russia and the USA. Nanofiber Solutions is currently engaged with leading hospitals and research
institutions across the world on nanofiber-based scaffolds for research and clinical applications ranging from stem
cell therapies to soft tissue regeneration to organ replacement.
Brian Kaspar, Ph.D.
Associate Professor
Department of Pediatrics and Children's Research Institute
CRMCBT
The Ohio State University
9
Brian K. Kaspar, Ph.D. is Associate Professor and Principal Investigator at The Ohio State University and The
Research Institute at Nationwide Children's Hospital in Columbus, Ohio. His graduate education was at University
of California San Diego specializing in molecular pathology. After graduate study, he performed post-graduate work
at The Salk Institute for Biological Studies in La Jolla, CA in the laboratory of Dr. Fred H. Gage where he pioneered
various methodologies in viral gene transfer for neurological disorders. After finishing his training in 2004, he
moved to The Ohio State/Nationwide Children's to start a laboratory focused on understanding and developing
treatments for severe neuromuscular disorders. In 2009, Dr. Kaspar's group identified the first viral vector capable
of traversing the blood brain barrier and utilized these findings to treat various neurological disorders, resulting in a
number of high impact publications. Dr. Kaspar serves as an Editor for the journal Molecular Therapy.
Periannan Kuppusamy, Ph.D, M.D.
D Litt, William D. and Jacquelyn L. Wells Chair in Imaging Research, Professor
Internal Medicine & Biomedical Engineering
Associate Director, Cardiovascular Medicine
CRMCBT
The Ohio State University
Dr. Kuppusamy is a Professor in the Department of Internal Medicine at OSU. He holds the William D. and
Jacquelyn L. Wells Chair in Imaging Research. He also serves as the Associate Director (for Research) of the
Division of Cardiovascular Medicine.
Dr. Kuppusamy received his doctoral (PhD) degree in magnetic resonance imaging. Following a Fogarty
Fellowship from the National Institutes of Health (NIH), he joined the Johns Hopkins University School of
Medicine, Division of Cardiology in 1987 and moved to the Ohio State University in 2002. Dr. Kuppusamy’s
research interests include oxygen and redox biology in cardiovascular diseases and cancer. He is well-known for his
expertise in the development of imaging methods for imaging oxygen and free radicals in biological systems. Dr.
Kuppusamy has received numerous research awards including: Silver Medal in 2006 for significant contribution to
the development of EPR imaging for biomedical applications, Doctorate of Medicine (honoris causa) in 2008 from
University of Pecs (Pecs, Hungary) for cardiovascular research, and 2011 Lumley Interdisciplinary Research Award
collaborative research at OSU. Dr. Kuppusamy has published over 330 peer-reviewed research manuscripts in
leading scientific journals. He has received several research grants from the National Institutes of Health and
American Heart Association.
Justin Lathia, PhD
Assistant Staff/Assistant Professor, Department of Cell Biology
Assistant Professor, Molecular Medicine
Cleveland Clinic Lerner College of Medicine
National Center for Regenerative Medicine
Dr. Justin Lathia is an Assistant Professor in the Department of Cell Biology at the Lerner Research Institute, part of
the Cleveland Clinic. He is also an Assistant Professor of Molecular Medicine at the Cleveland Clinic Lerner
10
College of Medicine and an Associate Member of the Case Comprehensive Cancer Center. Justin received a B.S.
and M.S. from Drexel University in Philadelphia, PA. While at Drexel, he developed targeted ultrasound contrast
agents which preferentially bound to newly formed vessel in breast cancer models. As part of the NIH-Cambridge
Graduate Partnership Program, Dr. Lathia completed his doctoral dissertation at both the National Institutes of
Health and Cambridge University in the U.K. His worked focused on the role of cell adhesion molecules during the
development of the nervous system. After completing his Ph.D. he completed post doctoral fellowships at Duke and
the Cleveland Clinic where he focused on the role of cell adhesion in regulating stem cell like cells in brain tumors.
Dr. Lathia’s current research efforts involve deciphering how individual cells within the tumor hierarchy
communicate with one another. His lab is developing imaging models with brain tumor stem cells to interrogate
these communication mechanisms.
He has co-authored over 50 publications and has received grants from the American Brain Tumor Association and
NIH, most recently a K99/R00 Pathway to Independence Award.
Zhenghong Lee, PhD
Associate Professor of Radiology
Biomedical Engineering
Case Center for Imaging Research
National Center for Regenerative Medicine
Dr. Lee’s research interests are in the areas of cancer and stem cell imaging. In his stem cell research, he labeled
progenitor cells such as mesenchymal stem cells with radionuclide, reporter gene system for track their
implant/transplant. Further development including imaging the function of stem cells such as differentiation. He has
moved his imaging research towards translation by going from mouse models to the large porcine models and
working with clinicians for human trials. In his cancer imaging research, he has focused on small molecule PET
imaging tracers, and studies their uptake and retention (in the tumor) mechanisms. Part of this is for evaluating the
full clinical utility for these radio-tracers.
Jianjie Ma, Ph.D.
Director, Division of Molecular Medicine
CRMCBT
The Ohio State University
Jianjie Ma, PhD, joins The Ohio State University as Professor in the Department of Surgery, the Karl P. Klassen
Chair of Thoracic Surgery in the Department of Surgery, on July 1, 2012. He will also be engaged as a Davis Heart
Lung Research Institute Investigator and serve on the advisory committee of the newly formed Center for
Regenerative Medicine and Cell-Based Therapies in the College of Medicine.
Dr. Ma comes to Ohio State from the Robert Wood Johnson Medical School at the University of Medicine and
Dentistry of New Jersey (UMDNJ) where he is a university-named professor and acting chair of the Department of
Physiology and Biophysics, as well as Chief of the Division of Developmental Medicine and Research. During his
11
time at UMDNJ, Dr. Ma founded the Graduate Program in Physiology and Integrative Biology, which is jointly
sponsored by UMDNJ and Rutgers University. He served on the Scientific Advisory Board for the Cancer Institute
of New Jersey. In addition, he served on several National Institutes of Health study sections and various editorial
boards.
In addition to his faculty appointment with UMDNJ, Dr. Ma also founded his own company, TRIM-edicine Inc., a
university spinoff biotechnology company. TRIM-edicine develops novel biopharmaceutical products for the
treatment of several important unmet medical needs. One specific therapeutic protein is MG53, which targets
diseases involved chronic and acute tissue damage. The other drug is ATAP, which targets apoptosis for cancer
treatment.
Dr. Ma is an NIH-funded researcher, prominently and widely published on the topics of muscle physiology, aging,
cardiovascular disease, cystic fibrosis, apoptosis and cancer biology. He has authored more than 130 publications
and holds 10 patents. He has assembled an international team of collaborators working on translational research. His
group maintains close collaboration with pharmaceutical industries for joint development efforts toward translating
basic discovery into clinical application.
Dr. Ma received his bachelor’s degree in Physics from Wuhan University in China, and came to the United States
through the CUSPEA (China-US Physics Examination Application) program after his undergraduate education. He
was chosen to represent the Department of Physiology and Biophysics at the Graduate Student Symposium of
Baylor College of Medicine, where he received his PhD in 1989. Dr. Ma went on to become an Instructor of
Physiology at Rush Medical College (1989-1991) where he received postdoctoral fellowship and research grants
from the Muscular Dystrophy Association, and a University Committee on Research Grant Award. Dr. Ma joined
the Department of Physiology and Biophysics at Case Western Reserve University in 1992, and became a tenured
Associate Professor in 1997. In 2001, he was recruited to UMDNJ as a university-named professor.
Dr. Ma has trained numerous graduate and postgraduate students, and many of them have become leaders in
academia, industry, medicine and law firms. He was an established investigator for the American Heart Association
(AHA) and served as advisor for many AHA postdoctoral and scientist development fellows. He is an outstanding
mentor and educator, and has coordinated the teaching of both medical and graduate students at Case Western
Reserve University as well as the Robert Wood Johnson Medical School. He is also actively involved in teaching
and collaboration with the Chinese Academy of Sciences and universities in China.
Nicanor I. Moldovan, PhD
Research Associate Professor
Cardiovascular Medicine
Davis Heart and Lung Research Institute
CRMCBT
The Ohio State University
Dr. Moldovan earned his MS in Biophysics at University of Bucharest, Romania and PhD in Cell Biology at the
Institute of Cellular Biology and Pathology, Bucharest, Romania. After a post-doctoral fellowship in Experimental
Cardiology at Johns Hopkins University in Baltimore, MD, he was recruited at Davis Heart and Lung Research
Institute in Columbus, OH. He is an affiliated Faculty in Biomedical Engineering and in the Graduate Programs of
Biophysics and Integrated Graduate Biosciences Program. He organized an International Symposium on the biology
of circulating progenitor cells, and edited a monograph on this topic. He is Assistant Editor and Guest Editor for
Regenerative Medicine at the Journal of Cellular and Molecular Medicine. Dr. Moldovan was awarded a very
competitive ARRA RC2/'Grand Opportunities' stimulus grant, for the study of endothelial progenitor cells.
Currently, in collaboration with physicians and engineers, Moldovan lab is developing the following projects in the
field of Regenerative Medicine: A) Identification and characterization of circulating progenitor cells using Systems
Biology principles (“Repairome”) and cytomics (single-cell level) methods, for diagnostic and prognostic purposes.
12
B) Tissue engineering of peri-implant space using stem/progenitor cells and fibrous synthetic scaffolds, for the
control of foreign body reaction; C) Modeling of cellular robustness using experimental methods and computational
stochastic mechanics, for cell therapy applications.
George Muschler, MD
Professor of Orthopaedic Surgery
Specialist in Joint Replacement Surgery
and Treatment of Fracture Non-union
Vice Chairman, Orthopaedic and Rheumatologic Institute
Director, Orthopaedic & Rheumatologic Research Center
Director, Clinical Tissue Engineering Center
Cleveland Clinic Lerner College of Medicine at Case Western Reserve University
Cleveland Clinic
National Center for Regenerative Medicine
Dr. Muschler is an Orthopaedic surgeon specializing in adult reconstructive surgery and the treatment of fracture
non-union and serves as Vice Chairman of the Orthopaedic and Rheumatologic Institute in the Cleveland Clinic.
Dr. Muschler’s laboratory in the Department of Biomedical Engineering at the Cleveland Clinic is focuses on
challenges in adult stem cell biology, tissue engineering and regenerative medicine. Dr. Muschler has served as a
leader in developing multi-institutional collaborative translational networks. He currently serves as Director of the
Clinical Tissue Engineering Center (CTEC), an Ohio-based network. Dr. Muschler served as a Co-Director of the
Armed Forces Institute of Regenerative Medicine (AFIRM), a national network funded by the Department of
Defense and dedicated to the acceleration of development of improved therapies to serve wounded warriors, from
March 2008 to May 2010.
Dr. Muschler earned his undergraduate degree in Chemistry at the University of Illinois in Champaign-Urbana in
and his M.D. at Northwestern University School of Medicine in Chicago, Illinois. He completed his residency in
Orthopaedic Surgery at the University of Texas Southwestern, Dallas, Texas, and fellowship training in
Musculoskeletal Oncology and Metabolic Bone Disease at The Memorial Sloan-Kettering Cancer Center and The
Hospital for Special Surgery, New York, New York.
Ichiro Nakano, MD, PhD,
Associate Professor
Director of Neural Cancer Stem Cell Program
Department of Neurological Surgery
James Comprehensive Cancer Center
CRMCBT
The Ohio State University
Ichiro Nakano, MD, PhD, is an Associate Professor and Director of Neural Cancer Stem Cell Program at the Ohio
State University, Department of Neurological Surgery.
Through his career, Dr. Nakano trained as an academic neuro-oncology surgeon conducting both clinical practice
and brain tumor research. As a neurosurgeon, he primarily treats patients with brain tumors, and as a scientist, the
Nakano lab focuses on experimental therapeutics targeting malignant brain tumors. Since appointed to the OSU
13
Medical Center in 2009, Dr. Nakano and his lab members have sought to develop novel therapeutics targeting
cancer stem cells in malignant gliomas.
Dr. Nakano’s long-term goal is to contribute to achieve better care of patients with brain tumors by identifying novel
and innovative therapies. He continues to devote myself towards improving the outcomes of patients by developing
effective therapies for these devastating diseases.
Lynn O’Donnell, Ph.D.
Director, Cell Therapy Laboratory
OSUCCC – James Cancer Hospital and Solove Research Institute
Dr O’Donnell received her doctoral degree in microbiology at The Ohio State University, where she continued her
career as a research scientist in hematology before taking the position as Director of the Cell Therapy Laboratory in
the James Cancer Hospital. This clinical laboratory serves dual functions. The first is to support the Blood and
Marrow Transplant Program by processing hematopoietic stem cells from marrow, peripheral blood and cord blood
for clinical transplantation. This high volume, moderate complexity service line is subject to many of the same
regulations and process control concepts as more complex processes that are the second function of the Laboratory –
namely – supporting clinical trials in novel cellular therapies and regenerative medicine. This includes translational
development to bring the “first-in-human” products to patients, as well as working with industry sponsors and
collaborators on multi-center studies with either local, shared or centralized cell product manufacturing. Under Dr.
O’Donnell’s direction, the Cell Therapy Laboratory has been able to independently develop complex processing
methods, such as pancreatic islet isolation, from the ground up. In addition, we have worked extensively with
corporate sponsors in shared manufacturing arrangements, which has allowed us to develop considerable expertise
in the complicated logistics of such arrangements, a point which is frequently overlooked. Dr. O’Donnell frequently
presents the Laboratory’s work at national and international meetings and serves on numerous working committees
in the field of cellular therapy, with leadership positions that eventually led to her elected position as Secretary of
the International Society of Cellular Therapy and a past member of the Cellular Therapy Section Steering
Committee of AABB.
Mike Paulaitis, Ph.D.
Ohio Eminent Scholar Professor
Director, Institute in Multi-scale Modeling of Biological Interactions
Chemical and Biomolecular Engineering
CRMCBT
The Ohio State University
Michael Paulaitis, PhD received his BS degree in chemical engineering from Princeton University and his PhD in
chemical engineering from the University of Illinois. He joined the OSU Department of Chemical and Biomolecular
Engineering in 2005, after faculty appointments at the University of Delaware and at Johns Hopkins University,
where he also co-directed the Institute for Multi-Scale Modeling of Biological Interactions and the Burroughs
Wellcome Fund Program in Computational Biology. He is currently an Ohio Eminent Scholar in Nanobiotechnology
and Molecular Self-Assembly, and chairs the Executive Committee of the National Science and Engineering Center
14
for Affordable Nanoengineering of Polymeric Biomedical Devices. Research in the Paulaitis lab is focused on the
role protein-protein interactions play in molecular recognition and self-assembly in aqueous environments and at the
interfaces. The lab’s recent research activities have been in the development of cellular microarrays for screening
antigen-specific T-cell responses and in characterizing the biophysical properties of cancer cell-secreted
microvesicles as they relate to microvesicle targeting and internalization mechanisms in cell-cell signaling.
Jeremy Rich, MD
Chairman, Department of Stem Cell Biology and Regenerative Medicine
Lerner Research Institute
Cleveland Clinic
Co-Director, National Center for Regenerative Medicine
Jeremy N. Rich, MD is Chairman and Staff of the Department of Stem Cell Biology and Regenerative Medicine,
Co-Director of the Center for Stem Cell and Regenerative Medicine (CSCRM) in the National center for
Regenerative Medicine, and Staff in the Department of Neurology, the Taussig Cancer Center, and the Brain Tumor
and Neuro-Oncology Center. He graduated summa cum laude from Washington University in St. Louis with a
Bachelor’s in Science in Electrical Engineering then graduated from Duke University School of Medicine. He
subsequently trained in internal medicine and neurology at The Johns Hopkins Hospital where he served as Chief
Resident in Neurology. He completed a Fellowship in Neuro-Oncology at Duke University Medical Center and
served on faculty, achieving rank as Associate Professor with Tenure, until moving to Cleveland Clinic in
September 2008 as the inaugural Chairman of the Department of Department of Stem Cell Biology and
Regenerative Medicine. Dr. Rich focuses on one of the deadliest types of cancer, brain tumors, as both a physician
and scientist. His research has contributed to understanding brain cancer from the perspective of stem cell biology.
His laboratory has identified cancer stem cells as an explanation of resistance to radiotherapy and as drivers of the
growth of new blood vessels to feed the tumor. This research may serve to identify new treatments for brain cancer
that will hopefully translate into improved survival for patients. Dr. Rich has received a number of awards,
including naming as a Damon Runyon-Lilly Clinical Investigator, Sidney Kimmel Foundation for Cancer Research
Scholar, and election to the American Society for Clinical Investigation.
Cameron L. Rink, Ph.D.
Assistant Professor, Surgery
CRMCBT
The Ohio State University
Cameron Rink, PhD is an Assistant Professor of Vascular Diseases and Surgery at The Ohio State University
Wexner Medical Center. The central focus of the Rink laboratory is to understand neural and cerebrovascular
adaptations that protect the brain from ischemic stroke injury. These adaptations include the formation and
recruitment of collateral blood supply to improve perfusion at the stroke-affected site, and mechanisms of poststroke neuroplasticity that facilitate recovery from stroke-induced loss of motor function. Pro-arteriogenic factors
(TIMP1, CLIC1, CLIC4) are the mechanistic focus in studies addressing cerebrovascular collaterals, while the
family of neurotrophins are currently being investigated for their role in neuroplasticity and post-stroke functional
recovery in conjunction with mechanical therapy. The laboratory employs pre-clinical stroke models (small and
large animal) to study nutritional and mechanical interventions against stroke. Technology platforms used by the lab
15
include magnetic resonance imaging (T2 weighted imaging and DTI-based tractography), laser speckle flowmetry,
laser capture microdissection (LCM), corrosion cast with scanning electron microscopy (SEM), and softwareassisted sensorimotor testing.
Chandan Sen, Ph.D.
Director, Center for Regenerative Medicine and Cell Based Therapies
Associate Dean, Translational & Applied Research
Professor and Vice-Chairman, Surgery
Director, OSU Comprehensive Wound Center
Deputy Director, Davis Heart and Lung Research Institute
Dr. Chandan Sen is the Director of Ohio State University’s Comprehensive Wound Center, home to NIH-funded
research, clinical trials as well as care-provider to 1500 patient visits a month. Dr. Sen is Associate Dean for
Translational and Applied Research at The Ohio State University Medical Center. After completing his Masters of
Science in Human Physiology from the University of Calcutta, Dr. Sen received his PhD in Physiology from the
University of Kuopio in Finland. Dr. Sen trained as a postdoctoral fellow at the University of California at
Berkeley's Molecular and Cell Biology department. His first faculty appointment was in the Lawrence Berkeley
National Laboratory. In fall of 2000, Dr. Sen moved to The Ohio State University where established a program on
tissue injury and repair. Currently, Dr. Sen is a Professor and Vice Chair (Research) of Surgery. His research
program is housed in the Davis Heart and Lung Research Institute where he serves as a Deputy Director and
Director of the Regenerative Medicine Program. He is the Director of the Novel Clinical and Translational
Methodologies Program as well as of the Pilot Studies Program of the NIH Center for Clinical and Translational
Sciences at Ohio State. Dr. Sen is the chairman of the Surgery, Anesthesiology & Trauma study section of the NIH.
Dr. Sen is the Editor-in-Chief of the #1 rated journal in redox biology Antioxidants & Redox Signaling (impact
factor 8.209). He is also an Associate Editor of the prestigious American Physiological Society journal Physiology
Genomics. Dr. Sen is the Editor-in-Chief of the Wound Healing Society’s yearbook publication Advances in Wound
Care (www.liebertpub.com/adwc <http://www.liebertpub.com/adwc <http://www.liebertpub.com/adwc> > ).
Dr. Sen has published over 300 articles and is cited 1400+ times a year in the literature.
Toshiharu Shinoka, M.D., Ph.D.
Co-Director, Tissue Engineering Program
Nationwide Children’s Hospital
Toshiharu Shinoka, M.D., Ph.D. As a pediatric cardiovascular surgeon, Dr. Toshiharu Shinoka is interested in the
surgical management of congenital heart anomalies. Repair of many congenital heart defects often requires foreign
materials to establish vascular continuity. Prosthetic and bioprosthetic materials currently in use lack growth
16
potential and therefore must be repeatedly replaced in pediatric patients as they grow. Tissue engineering (TE) is a
new discipline that offers the potential for creating replacement structures from autologous cells and biodegradable
polymer scaffolds. In May 2000, Dr. Shin’Oka and colleagues initiated clinical application of tissue-engineered
vascular grafts seeded with cultured cells at Tokyo Women’s Medical University. Forty seven patients underwent
cardiac surgery with a tissue-engineered graft. Biodegradable conduits or patches seeded with autologous BMCs
showed normal function (good patency up to maximum follow-up of 7years). As living tissues, these vascular
structures may have the potential for growth, repair and remodeling. The TE approach may provide an important
alternative to the use of prosthetic materials in the field of pediatric cardiovascular surgery. His laboratory was the
first to obtain FDA approval for investigating the use of tissue engineered vascular grafts. Dr. Shin’Oka received his
medical degree at Hiroshima University, School of Medicine and attended Tokyo Women’s Medical University to
receive his Ph.D. in Cardiac Surgery.
Edward L. Snyder, MD, FACP
Professor Laboratory Medicine, Yale Medical School,
Director Transfusion/Apheresis/Cell Therapy and Tissue Services, Yale New Haven Hospital, New Haven,
CT 06520
Edward L. Snyder, MD graduated from New York Medical College. He was a Resident in Internal Medicine and a
Hematology Fellow at Montefiore Hospital in the Bronx, New York. He was a fellow in Transfusion Medicine, also
at Montefiore Hospital. Dr. Snyder is currently Professor of Laboratory Medicine at Yale University Medical
School, Vice-Chair for Clinical Affairs, Director of Blood and Tissue Bank/Apheresis Services at Yale-New Haven
Hospital and Director of the Richard Frisbee Hematopoietic Cell Processing Laboratory at Yale Medical Center. Dr.
Snyder is ABIM board certified in Internal Medicine and Hematology and ABP board certified in Transfusion
Medicine. Dr. Snyder is also Associate Director of Membership Services for the Yale Comprehensive Cancer
Center. He was President of the American Association of Blood Banks from 1997 – 1998 and a past member the
FDA Blood Products Advisory Committee. Dr. Snyder has served on numerous governmental advisory panels and
is currently Chairman of the NHLBI, DSMB for Red Cell Storage, a member of the NHLBI DSMB for the TM/HT
CTN, and a member of the NHLBI K23/K24 Career Development Award Study Section. A member of the FDA
CDRH Hematology and Pathology Devices Panel, Dr. Snyder is Past Chairman of the National Marrow Donor
Program (NMDP) Board of Directors. Dr. Snyder is an Associate Editor of Transfusion and has been a member of
the Editorial Board of Blood. He has over 300 publications in the field of Transfusion Medicine. His current
research interests include studies of: isolation of MNCs for manufacture of blood vessels by regenerative medicine
techniques, leukoreduction filters; the platelet storage lesion; evaluation of new apheresis technologies, and
hematopoietic stem cell mobilization, collection and processing.
Gil Van Bokkelen Ph.D.
Chairman and CEO, Athersys, Inc.
Dr. Van Bokkelen has served as our Chief Executive Officer and Chairman since August 2000. Dr. Van Bokkelen
co-founded Athersys in October 1995 and served as Chief Executive Officer and Director since Athersys' founding.
Prior to May 2006, he also served as Athersys' President. Dr. Van Bokkelen is the current Chairman of the Alliance
for Regenerative Medicine, a Washington D.C. based consortium of companies, patient advocacy groups, disease
foundations, and clinical and research institutions that are committed to the advancement of the field of regenerative
medicine. He is also the Chairman of the Board of Governors for the National Center for Regenerative Medicine,
and serves on a number of other boards, including the Biotechnology Industry Organization's ECS board of directors
17
(from 2001 to 2004, and from 2008 to present), the McGowan Institute for Regenerative Medicine and the
Regenerative Medicine Foundation. He received his Ph.D. in Genetics from Stanford University, his B.A. in
Economics from the University of California at Berkeley, and his B.A. in Molecular Biology from the University of
California at Berkeley.
Horst von Recum, PhD
Associate Professor
Departments of Biomedical Engineering; Macromolecular Science and Engineering
Case Western Reserve University
National Center for Regenerative Medicine
The goal of the von Recum lab is to investigate the therapeutic delivery of molecules and cells. To that end we have
two specific areas of expertise. The first area is the therapeutic delivery and differentiation of pluripotent stem
cells. We have applied this strategy toward vasclogenesis in tissue engineering scaffolds, as well as generation of
cardiac tissue patches, motor neurons, and T-cells. The second area of expertise is a novel polymeric drug delivery
platform which has the capacity for delayed, linear release of active agents through affinity-based mechanisms,
substantially slower and more linear than conventional diffusion-based mechanisms. With this platform we are
exploring the delivery of small molecule drugs such as antibiotics, as well as proteins at therapeutically efficacious
time frames and dosing regimens. These two areas of expertise rely on my diverse training from chemical
engineering, to gene therapy to embryonic stem cells.
Jennifer Yu, MD, PhD
Associate Staff, Radiation Oncology
Adjunct Staff, Stem Cell Biology and Regenerative Medicine
Cleveland Clinic
Jennifer Yu, MD, PhD, is a practicing physician in Radiation Oncology with a joint appointment as a cancer
researcher in Stem Cell Biology and Regenerative Medicine. With a BS from Yale University, Dr. Yu earned her
MD and PhD degrees from Columbia University. Dr. Yu comes to Cleveland Clinic from the University of
California, San Francisco, where she completed her residency and research fellowship. She is interested in
improving radiation therapy for glioblastomas, a particularly aggressive and devastating brain tumor, and preventing
radiation-inducedbrain malignancies. Hyperthermia – heating the tumor cells –has been found to increase the
efficacy of radiation in patients. She aims to understand the mechanism responsible for this and the role played by
glioma stem cells. Dr. Yu is also interested in developing mouse models of radiation carcinogenesis. She is using a
p53-mutant mouse model to discover molecular drivers of secondary malignancies, with the goals of preventing
radiation-induced cancers and identifying therapeutic targets for these tumors.
18